To elucidate how pyridoxine-refractory X-linked sideroblasthe sizes of which were larger than that of mature ALAS-E, was found in mitochondria. The proteins were reproducibly tic anemia (XLSA) develops, we analyzed the erythroid-specific 5-aminolevulinate synthase (ALAS-E) gene of a patient detected in assays combining in vitro transcription/translation of ALAS-E precursor and import of the precursor into with the anemia. The activity and amount of the enzyme in bone marrow cells of the patient were found to be approxiisolated mouse mitochondria. These results suggest that the mutation causing pyridoxine-refractory XLSA affects the mately 5% of the normal control. We identified a point mutation, which introduces an amino acid substitution from is also encoded, causing an amino acid substitution (I 471 to and increased tissue iron levels. Hereditary sideroblastic anemia can be either X chromosome-linked (XLSA) or au-N) that resulted in an enzyme with weaker activity. Because the patient recovered after pyridoxine administration, this tosomal. XLSA has been further subdivided into pyridoxineresponsive and pyridoxine-refractory types based on reamino acid substitution possibly affected the affinity of the enzyme for the cofactor. Shortly after, the first pyridoxinesponse to pyridoxine treatment.
S
The X chromosomal assignment of the ALAS2 gene suggested that mutations in this locus might cause XLSA. In IDEROBLASTIC ANEMIA comprises a heterogeneous group of disorders, 1,2 which encompass hereditary types, characterized by common features including large 1992, Cotter et al 16 identified a point mutation in the exon 9 region of the ALAS2 gene of a patient with suspected numbers of ring sideroblasts in bone marrow, hypochromic erythrocytes in peripheral blood, ineffective erythropoiesis, XLSA, where a lysine residue (K 391 ) critical for PLP binding 7 is also encoded, causing an amino acid substitution (I 471 to and increased tissue iron levels. Hereditary sideroblastic anemia can be either X chromosome-linked (XLSA) or au-N) that resulted in an enzyme with weaker activity. Because the patient recovered after pyridoxine administration, this tosomal. XLSA has been further subdivided into pyridoxineresponsive and pyridoxine-refractory types based on reamino acid substitution possibly affected the affinity of the enzyme for the cofactor. Shortly after, the first pyridoxinesponse to pyridoxine treatment. 1 Reduced levels of 5-aminolevulinate (ALA) synthase responsive XLSA kindred was reported, having a point mutation in the ALAS2 gene at a position (T 388 to S). 17 Recently, [EC2.3.1.37] activity in the mitochondria of bone marrow cells are found in most congenital sideroblastic anemia paseveral kindred with pyridoxine-responsive XLSA due to ALAS2 mutations were reported. [18] [19] [20] tients. [3] [4] [5] In the initial regulatory step of heme biosynthesis, which requires pyridoxal 5-phosphate (PLP), 6 ,7 ALA synHowever, no link between ALAS2 and pyridoxine-refractory type XLSA has been shown and available data is still thase catalyzes the condensation of succinyl-CoA and glycine to form ALA in mitochondrial matrices. Recent evirather limited. Although some ALAS2 mutations were reported in pyridoxine-refractory XLSA patients, 21 ,22 characdence shows that erythroid-specific (ALAS-E) and nonspecific (ALAS-N) isozymes of ALA synthase exist in terization of the mutant proteins has not yet been described. In two other XLSA cases (one pyridoxine-refractory and the vertebrates [8] [9] [10] ; ALAS-E is restricted to erythroid cells, 11 but ALAS-N is expressed in all tissues examined including bone other partially pyridoxine-responsive), ALA synthase activity was increased in whole lysate from bone marrow cells, 23 marrow cells. Human genes encoding ALAS-E (ALAS2) and ALAS-N (ALAS1) have been mapped to chromosomal rebut no mention was made of whether these cases had mutation(s) in the ALAS2 gene. gions Xp11.21 and 3p21.1, respectively. [12] [13] [14] [15] To elucidate the mechanisms of pyridoxine-refractory XLSA, we analyzed the ALAS2 gene of a patient and found Promoter and 1st exon  5-GATGGTCTGATTCCAAAGCC-3  5-TGTGTACAGCCCTGAGAGAC-3  2nd exon  5-CGAGGATCAAAGGCTTGGCT-3  5-GGCCAGTATAACTTGGAACT-3  3rd exon  5-GGGGTACATTAGATATCAGC-3  5-ATTAGCCTAGCTCAGGACTG-3  4th exon  5-CACATGCTTTCTTTTTCCCC-3  5-GATGCCTTCCCTATTCCGGT-3  5th exon  5-ATACAGACTAGCCAGGGAGA-3  5-AAGTTTCCACTGCCAGCTCT-3  6th exon  5-AACATTGACTCCCATCAAGG-3  5-CTGGATGCTGTATTGCAGGA-3  7th exon  5-CCAGGTCAAACCTGAAGGTT-3  5-TTTTGTGAGACCAACACTAG-3  8th exon  5-GAAGGTTATGATGTCCTACC-3  5-AAGAATTTTGTAAGGGCCTC-3  9th exon  5-CATGATCCTGTTGCTCTGGA-3  5-AGCGTGAGGCTCCCAGAATA-3  5 of 9th exon  5-CATGATCCTGTTGCTCTGGA-3  5-GCATGTGCTTGACATTGCGC-3  3 of 9th exon 5-ACCCGTGACTTGGTGGACAT-3 5-AGCGTGAGGCTCCCAGAATA-3 10th exon 5-ATCTGCTTAATGGAGCTAGT-3 5-AAACTCAGTGGTCTCTGTCC-3 nested 5-CCAGAGTGGCAGGTACTGTT-3 5-GCTTCTCTTTCAGATCCTGG-3 11th exon 5-TGGCTCATCTGTACTGTGAC-3 5-TGACCAACAAGTGACCTATG-3 3rd intron 5-GGGAAGAGCAAGATTGTGCA-3 5-GAATCAGGTGTGTGACCTTC-3 4th intron 5-GAAGGTCACACACCTGATTC-3 5-ACACACGGTAGGTGTGATCC-3
Authenticity of the PCR fragment was verified by sequence analysis. viously. 18 Cells were harvested by centrifugation, resuspended in Buffer A (50 mmol/L HEPES [pH 7.5], 1 mmol/L EDTA, and 5 Genomic clones were obtained by screening lEMBL3 human leukocyte and TE1 (human esophageal cancer cell line 25 ) cell libraries mmol/L dithiothreitol [DTT]) containing 0.1% Triton X100 and frozen at 080ЊC. Samples were thawed on ice, sonicated, and centriwith human ALAS2 cDNA fragments. PCR amplification of high molecular weight DNA isolated from normal human peripheral leufuged, and the supernatant fractions applied to a Glutathione Sepharose 4B affinity column (Pharmacia Biotech). The fusion proteins kocytes was performed to obtain genomic DNA fragments spanning exon 4, and two sets of primers were prepared to allow isolation of were eluted with Buffer A containing 5 mmol/L glutathione, dialyzed, cleaved with Factor Xa (1 mg/50 mg protein), and reapplied fragments covering introns 3 (hAEi3) and 4 (hAEi4) ( Table 1) .
Epstein-Barr virus (EBV)-transformed cell lines.
Lymphocytes to a Glutathione Sepharose 4B affinity column. The unbound proteins were used in the ALA synthase activity assays as described from the peripheral blood of proband, his mother, and sister were isolated and transformed with EBV. They were cultured and harpreviously.
32
Immunoblot analysis of ALAS-E. Bone marrow samples obvested as described previously. 26 Sequence analysis of ALAS2 gene. DNA was prepared from tained from sideroblastic and iron deficiency anemia patients with their informed consent were used in ALA synthase activity assays. 33 cultured EBV-transformed lymphoblastoid cells with the genomic DNA purification system (TurboGen, Invitrogen, San Diego, CA) Nucleated cells and erythroblasts (EBLs) were counted. The cells were collected in the presence of heparin and washed twice with and used for amplification to obtain the ALAS2 exons and 250 bp of the promoter region with a slight modification of the method in 1.15% KCl in 10 mmol/L Na phosphate buffer (pH 7.5). Red blood cells were disrupted by a 10-minute incubation on ice after addition Saiki et al. 27 The PCR mixture (100 mL) contained 0.5 mg of genomic DNA, dNTPs (20 mmol each), 100 pmol primers (see Table 1), 11 of 10-fold volume of cold H 2 O. Samples were made isotonic with 11.5% KCl, centrifuged at 44,800g for 30 minutes, washed twice Tth DNA polymerase buffer and 2.5 U Tth DNA polymerase (Toyobo, Osaka, Japan). Samples were denatured at 94ЊC for 5 minutes with 1.15% KCl, homogenized in 0.25 mol/L sucrose with a microscale Potter type homogenizer and stored at 080ЊC until use. followed by 30 cycles of amplification in a DNA Thermal Cycler (Perkin Elmer Cetus, Foster City, CA) with denaturation at 94ЊC for For immunoblot analysis, bone marrow samples containing 1 1 10 5 EBLs were homogenized in sodium dodecyl sulfate (SDS) sam-1 minute, annealing for 1 minute at 0ЊC to 5ЊC below the melting temperature of the primers, and extension at 72ЊC for 1 minute. PCR ple buffer (2% SDS, 50 mmol/L Tris HCl [pH 6.8], 100 mmol/L DTT, and 10% glycerol), boiled for 3 minutes, and centrifuged at products were purified by QIAEX agarose gel extraction system (QIAGEN Inc, Chatsworth, CA) and directly sequenced with the 12,000g for 1 minute. Supernatants were applied to a SDS/8% polyacrylamide-Laemmli gel, 34 transferred to a polyvinylidene difluoride Taq Dye-deoxy Terminator Cycle Sequencing system and DNA sequencer (model 373A; Perkin Elmer Cetus). PCR amplified genomic membrane, blocked overnight at 4ЊC with 5% skim milk in Trisbuffered saline (TBS), and incubated with a rabbit antirat ALAS-N DNA fragments of the patient and his family were subcloned into a ddT-tailed pBluescript KS(-) cloning vector and sequenced by the antibody 35 in TBS/0.05% Tween 20 followed by a secondary goat antirabbit IgG conjugated with horseradish peroxidase. Immune dideoxynucleotide method 28 using Sequenase version 2.0 (Amersham International, Buckinghamshire, UK).
complexes were visualized by the enhanced chemiluminescence (ECL) method (Amersham International). Expression of wild type and mutant ALAS-E as GST fusion proteins in E coli. An A 621 to T mutation was introduced into human Positive controls were obtained by administering allylisopropylacetamide to rats to induce liver expression of ALAS-N. The liver ALAS2 cDNA by site directed mutagenesis. 29 Wild type and mutant cDNA fragments (amino acids 125 to 587 encoding the papain resiscytosolic fraction containing a precursor form of rat ALAS-N was prepared. A mitochondrial fraction from K562H cells, a subline of tant core catalytic domain of ALAS-E 30 ) were subcloned into the BamHI site of a pGEX-3X prokaryotic gene fusion vector (Phara human leukemia cell line 36 with elevated ALAS-E mRNA levels (unpublished observations, May 1997) and rat reticulocyte lysate macia Biotech, Uppsala, Sweden), producing N-terminal GST fusions with Factor Xa-cleavable linkages, and confirmed by sequencwere also prepared and used as size standards.
Transient expression of ALAS-E in fibroblasts.
Eukaryotic exing ( Fig 1A) . These GST fusion proteins were introduced into E coli BL21 pLysS (Novagen Inc, Madison, WI) as previously described 31 pression plasmids of human wild type (pCAGG-AE) and mutant ALAS-E (pCAGG-mutTA and -mutAG; see below) were made by and purified by a slight modification of the method described pre- The patient's mother was also found to have mild anemia aliquots were added to SDS sample buffer and boiled for 3 minutes with slightly increased serum iron concentration (Table 2) before loading on a SDS/8% polyacrylamide Laemmli gel system. and increased red blood cell size distribution (red blood cell 
In vitro transcription/translation of ALAS-E precursor and import into mitochondria. cDNAs encoding V
190 mutant and wild type ALAS-E precursors were subcloned into pBluescript plasmids.
Peripheral Blood
RNAs were transcribed with the Riboprobe system (Promega) using Tokyo, Japan). 42 that of the mature ALAS-E is not known, as the proteolytic cleavage site has not been experimentally determined. One report predicted the size of the signal sequence in human ALAS-E precursor to be 49 amino acids and the molecular mass of the mature protein as 59.5 kD, 42 based on comparison with known cleavage sites for chicken and rat ALAS-N precursors. However, previous analysis of the mouse ALAS-E precursor 44 suggests that in mouse (and human) ALAS-E, the leader sequence may be 78 amino acids in length, which would predict a molecular mass of approximately 56 kD. 18 By SDS-PAGE, we have observed the sizes of rat ALAS-E precursor and mature forms to be 64 kD and 56 kD, respectively, 30 supporting the likelihood of the human mature form ALAS-E to be also 56 kD.
In human bone marrow cells, we detected an ALAS-E ALAS-E and ALAS-N are known to be easily degraded by papain and endogenous protease(s), 30, 35, 40 and, therefore, the slight size discrepancy may be due to partial degradation during the preparation of sample. Despite all attempts to for an additional 4 weeks, but the therapy was ineffective rapidly process the patient bone marrow aspirates, technical (Fig 2 and Table 2 ). A markedly elevated concentration of limitations in preserving the condition of clinical specimens serum ferritin was also found in this patient (Table 2) , sugstill exist. gesting that this patient is severely iron overloaded.
Structure of human ALAS2 gene. Although the structure of the human ALAS2 gene has been reported, the sequence information provided was insufficient to design primers for genetic analysis of the human ALAS2 locus. 41 We, therefore, obtained two lambda phage clones (lHEAL1a and lHEAL2a), which spanned the entire ALAS2 locus, with the exception of the region between intron 3 and exon 5. Regions covering intron 3, exon 4, and intron 4 were isolated by genomic PCR and three independent subclones for each fragment were sequenced. The sequence corresponding to exon 4 obtained from these genomic fragments was identical to that of the cDNA sequence 42 (data not shown), thus confirming the authenticity of these clones.
The surrounding sequences of all exon-intron boundaries were determined and 14 sets of primers were designed to allow PCR amplification of all exons, as well as the promoter region (Table 1 ). These primers gave reproducible results and their products could be used for direct sequence analysis of various DNA samples. To amplify exons 9 and 10, nested PCR was used as indicated in Table 1 .
Decrease of ALAS-E in patient's bone marrow cell mito- ALAS-E mature protein (Fig 3, lanes 1 and 2) and cross- The intensity of the ALAS-E band from proband's bone marrow EBLs (lane 5) was approximately 5% of that observed from the same number of EBLs from a female iron deficiency anemia patient (lane 4), whose ALA synthase activity falls within a normal range (data not shown). The decreased intensity of proband's ALAS-E band appears to correlate well with the reduction seen in the enzyme activity (see above), indicating that the decrease in ALA synthase activity in the bone marrow cells may be due to the reduced amount of ALAS-E.
Whereas the molecular mass of human ALAS-E precursor
Sequence analysis of the proband's genomic DNA. The structure of the ALAS2 gene of proband, his mother, and sister was analyzed by PCR amplification of all the exons, using the primers described in Table 1 , and sequence information was compiled. A single A to T transversion at nt 621 (nucleotide number corresponds to human ALAS2 mRNA sequence 42 ), in exon 5 (Fig 4B) , was the only difference between proband's sequence, that of reported cases [16] [17] [18] [19] [20] 45 and our normal controls (Fig 4A and also see below) . This A 621 to T transversion was found to be specific to one of the two To determine the effect of the V 190 mutation on ALAS-E activity, the enzyme activities of both mutant and wild type proteins were examined by expressing the papain resistant core catalytic domains 30 in E coli as fusion proteins with GST For personal use only. on April 18, 2017. by guest www.bloodjournal.org From (GST-mut and GST-AE). These were purified by affinity columns and cleaved with Factor Xa, to obtain Xa-AE (wildtype) and Xa-mut (mutant). The specific activities of GST-AE determined in the presence or absence of excess PLP (200 mmol/L) were found to be 5,507 { 100 and 3,817 { 389 nmol/h/mg, and those of GST-mut were 5,426 { 413 and 3,806 { 23 nmol/h/mg, respectively. The activities of Xa-AE and Xa-mut were comparable and found to be twice the levels of their GST-fusion counterparts (data not shown). The significance of this finding is that the specific activities of the mutant and wild-type enzymes are similar in the presence of excess amounts of PLP and reduction of the PLP concentration affects both in a like manner, indicating that the V 190 mutation is not critical for the enzyme activity of ALAS-E. This prompted us to look for other ways in which the mutation might influence the ALAS-E protein level and activity in the patient's bone marrow cells.
The V 190 mutant of ALAS-E can be incorporated into and functions in mitochondria. To elucidate how the V 190 mutation might cause the severe reduction in ALAS-E activity, we designed a method to examine the enzyme activity in eukaryotic cells. We expressed wild type and mutant ALAS-E proteins in a quail fibroblast cell line the accumulation of large amounts of porphyrins, the intermediate metabolic products of this pathway. Indeed, in the homogenates of QT6 fibroblasts expressing wild type ALAS-E, an intense red fluorescence could be detected Proteolytic cleavage of ALAS-E precursor is affected by under UV lamp illumination (Fig 5B, tube 2) , showing the V 190 mutation. We next examined whether normal prothat porphyrins and hence ALAS-E, are overproduced in cessing of the ALAS-E precursor V 190 mutant occurs after the cells. This fluorescence was not seen in cells transimport into mitochondria by analyzing the sizes of exogefected with control pCAGGS plasmid (tube 1). Expression nously expressed ALAS-E in QT6 cells by immunoblotting. of the V 190 mutant also gave rise to a clearly recognizable In the mitochondrial fraction of the QT6 cells transfected red fluorescence in QT6 cells (tube 3), albeit of a weaker with wild type ALAS2 cDNA, we observed two major bands intensity than that of the wild type enzyme. As succinyl- (Fig 6) ; the larger corresponds to the human ALAS-E precurCoA, a substrate of ALAS-E, is available exclusively in sor (64 kD), and the smaller band (58 kD) (lane 2) likely the mitochondrial matrix, 46 this result indicates that the corresponds to the mature form of ALAS-E (see Fig 3, lane V 190 mutant of ALAS-E is incorporated into mitochondria 3). Because the CAG promoter is capable of driving strong and can catalyze the formation of ALA from succinylexpression of ALAS-E, the rate of ALAS-E synthesis may CoA and glycine. Similar fluorescence patterns were obsurpass the rate of its mitochondrial import, therefore, enserved with culture supernatants (Fig 5C) and cell pellets abling the recovery of precursor protein, probably attached (data not shown) on exposure to UV light.
to mitochondria, in the mitochondrial fraction. A similar We then made an expression plasmid containing a mutaphenomenon can be observed when ALAS-N expression is tion of A 1328 to G, which we recently identified to be the induced strongly in rat liver by porphyrinogenic drugs (uncause of a reported case of pyridoxine-responsive sideroblaspublished observation, May 1997). Neither band was detic anemia 47 and introduced an amino acid substitution of tected in nontransfected QT6 cells (Fig 6, lane 1) . In the M 426 to Val (V 426 mutation) (unpublished observation, May V 190 mutant analysis (Fig 6, lane 3) , three bands were de-1997). Cells transfected with mutant plasmid showed only tected whose sizes were larger than that of the mature ALASmarginal red fluorescence (Fig 5B, tube 4 and Fig 5C, vial E. One band corresponds to the ALAS-E precursor, dis-4), demonstrating that the V 190 mutant enzyme present in playing a size similar to that detected in cells transfected pyridoxine-refractory patient retains almost intact enzyme with wild type plasmid. The other two bands, estimated to activity compared with the severe impairment observed with be 59.5 and 59 kD, are larger than the expected size of the the V 426 mutant enzyme found in the pyridoxine-responsive mature form of ALAS-E (58 kD, compare lanes 2 and 3). These bands were not detectable in the cytosol fraction of case.
For (lanes 1 to 3) and mitochondrial (lanes 4 to 6) fractions were analyzed by SDS-PAGE. Note that the sizes of the precursors are similar, but the processed mutant proteins are larger than the wild type.
the V 190 mutant transfected QT6 cells (data not shown) or tivity in vitro. However, on overexpression of wild type and mutant ALAS-E proteins in QT6 fibroblasts, two proteins in the mitochondrial fraction of erythroid K562H cells (see Fig 3, lane 3) , indicating that the V 190 mutation may affect with sizes larger than that of the wild type were observed in the mitochondrial fraction of V 190 mutant transfected cells. the processing of the ALAS-E precursor during or after import into mitochondria.
These bands were reproducibly detected in assays combining in vitro transcription/translation and import of the precursor. These results were further supported by analyses using an in vitro transcription/translation system to synthesize V 190 Therefore, it appears that the V 190 mutation affects the proteolytic processing of ALAS-E precursor during or after immutant and wild type precursors and in vitro transfer of the precursors into isolated mitochondria. While mature ALASport into mitochondria. This abnormal processing may result in proteins, which are unstable in bone marrow cells in vivo, E of a normal size could be detected in the mitochondrial fractions mixed with wild type precursor (Fig 7, lane 5 ), in causing a decreased level of ALAS-E protein and hence, reduced ALAS-E activity in mitochondria. the fractions with the V 190 mutant precursor, again the larger size band could be seen (Fig 7, lane 6) . In the in vitro
The processing of ALAS-E should be catalyzed by a mitochondrial processing peptidase that cleaves the signal seanalysis, only one aberrantly sized band was detected, in contrast to the observation of two larger sized bands from quences of various precursor proteins. 48 Evidence exists, which suggests that secondary or tertiary structural features the transfection analysis. This may be a reflection of the different experimental conditions (eg, in vivo £ in vitro, quail of the region surrounding the processing site may be important for the recognition and cleavage of signal secells £ mouse mitochondria). The consistent result of these analyses is that a larger form of ALAS-E occurs during quences. 49, 50 In line with this, a mutation downstream of the processing of the V 190 mutant precursor, indicating that it cleavage site in ornithine aminotransferase has been reported may undergo aberrant proteolytic processing during or after to affect its processing. 51 Additionally, Graf et al 52 reported transfer into mitochondria. We also noticed that the intensity that incorrectly processed preornithine transcarbamylase, of the processed band of the mutant ALAS-E (59.5 kD) is which is larger in size than the normal mature enzyme, has 42% of the precursor (64 kD band), while that of the normal been shown to be catalytically active, but more sensitive to mature ALAS-E protein (58 kD) is 87% of the precursor.
proteolytic degradation. Similarly, we could not detect the Smearing of the mutant band is observed, suggesting the abnormally processed ALAS-E protein in the bone marrow relative instability of the aberrantly processed protein in micells of the patient. This finding suggests that the abnormally tochondria as compared with the mature wild type protein.
processed ALAS-E precursor has probably undergone extensive proteolysis after import into mitochondria, although we DISCUSSION could not exclude the possibility completely that the mutant ALAS-E precursor may have degraded either before the imAnalysis of the ALAS2 locus of a pyridoxine-refractory port into mitochondria or after normally processed in mito-XLSA patient showed an A 621 to T transversion. This mutachondria in human bone marrow cells. Further analyses of tion showed X-linked inheritance and resulted in an Asp to the mitochondrial proteolytic degradation pathway is reVal change at position 190, where strong conservation of quired to elucidate the mechanisms by which the increased Asp (or Glu) residues is seen among ALAS-E proteins in degradation of mutant ALAS-E protein occurs. various species. 30 Despite marked decrease in both the activMolecular analyses of the ALAS2 gene in one pyridoxineity and protein level of ALAS-E in the patient's bone marrow responsive type XLSA case and five kindred have been recells, this hydrophilic to hydrophobic, acidic to neutral substitution did not seem to significantly affect the enzyme acported, [16] [17] [18] [19] [20] and in four of the six cases, amino acid substituFor personal use only. on April 18, 2017 . by guest www.bloodjournal.org From tions were found near the binding site of the PLP cofactor, in mitochondria causes both pyridoxine-responsive and -refractory XLSA. The confirmation for this conjecture must in addition to impaired ALAS-E activity. In this study, we showed that the expression of a pyridoxine-responsive type await the results of ALAS2 gene disruption, which are presently underway, to create an animal model for XLSA. In ALAS-E mutant in QT6 fibroblasts resulted in low porphyrin production. In the remaining two cases, mutations were addition, further investigation into the regulation of ALAS2 gene expression, as well as its mitochondrial import mechafound in exon 5, resulting in amino acid substitutions at positions far from the PLP-binding lysine. 18, 20 However, renisms and maintenance of stability within mitochondria are essential to better understand the pathogenesis of XLSA and sponse to pyridoxine treatment was seen in one case, 20 implicating decreased thermolability of mutant ALAS-E at low other related disorders. or normal PLP concentrations as the cause of the low ALA synthase activity. These results suggest that pyridoxine-re-ACKNOWLEDGMENT sponsive XLSA is caused by mutations in ALAS2, which 
